Literature DB >> 29162610

Angiography Versus Hemodynamics to Predict the Natural History of Coronary Stenoses: Fractional Flow Reserve Versus Angiography in Multivessel Evaluation 2 Substudy.

Giovanni Ciccarelli1, Emanuele Barbato1,2, Gabor G Toth3, Brigitta Gahl4, Panagiotis Xaplanteris1, Stephane Fournier1, Anastasios Milkas1, Jozef Bartunek1, Marc Vanderheyden1, Nico Pijls5, Pim Tonino6, William F Fearon7, Peter Jüni8, Bernard De Bruyne9.   

Abstract

BACKGROUND: Among patients with documented stable coronary artery disease and in whom no revascularization was performed, we compared the respective values of angiographic diameter stenosis (DS) and fractional flow reserve (FFR) in predicting natural history.
METHODS: The present analysis included the 607 patients from the FAME 2 trial (Fractional Flow Reserve Versus Angiography in Multivessel Evaluation 2) in whom no revascularization was performed. FFR varied from 0.20 to 1.00 (average 0.74±0.16), and DS (by quantitative coronary analysis) varied from 8% to 98% (average 53±15). The primary end point, defined as vessel-oriented clinical end point (VOCE) at 2 years, was a composite of prospectively adjudicated cardiac death, vessel-related myocardial infarction, vessel-related urgent, and not urgent revascularization. The stenoses were divided into 4 groups according to FFR and %DS values: positive concordance (FFR≤0.80; DS≥50%), negative concordance (FFR>0.80; DS<50%), positive mismatch (FFR≤0.80; DS<50%), and negative mismatch (FFR>0.80; DS≥50%).
RESULTS: The rate of VOCE was highest in the positive concordance group (log rank: X2=80.96; P=0.001) and lowest in the negative concordance group. The rate of VOCE was higher in the positive mismatch group than in the negative mismatch group (hazard ratio, 0.38; 95% confidence interval, 0.21-0.67; P=0.001). There was no significant difference in VOCE between the positive concordance and positive mismatch groups (FFR≤0.80; hazard ratio, 0.77; 95% confidence interval, 0.57-1.09; P=0.149) and no significant difference in rate of VOCE between the negative mismatch and negative concordance groups (FFR>0.80; hazard ratio, 1.89; 95% confidence interval, 0.96-3.74; P=0.067).
CONCLUSIONS: In patients with stable coronary disease, physiology (FFR) is a more important determinant of the natural history of coronary stenoses than anatomy (DS). CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov. Unique identifier: NCT01132495.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  angiography; coronary artery disease; fractional flow reserve; percutaneous coronary intervention

Mesh:

Year:  2017        PMID: 29162610     DOI: 10.1161/CIRCULATIONAHA.117.028782

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

Review 1.  Relief of Ischemia in Ischemic Cardiomyopathy.

Authors:  Francesco Moroni; Zachary Gertz; Lorenzo Azzalini
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

2.  Three-vessel fractional flow reserve measurement for predicting clinical prognosis in patients with coronary artery disease.

Authors:  Takashi Kubo; Hiroki Emori; Yosuke Katayama; Kosei Terada
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

3.  Evaluation of fractional flow reserve in patients with stable angina: can CT compete with angiography?

Authors:  Xin Liu; Yabin Wang; Heye Zhang; Youbing Yin; Kunlin Cao; Zhifan Gao; Huafeng Liu; William Kongto Hau; Lei Gao; Yundai Chen; Feng Cao; Wenhua Huang
Journal:  Eur Radiol       Date:  2019-03-18       Impact factor: 5.315

Review 4.  Assessment of coronary physiology - the evidence and implications.

Authors:  Noman Ali; Peysh A Patel; Christopher J Malkin
Journal:  Clin Med (Lond)       Date:  2019-09       Impact factor: 2.659

Review 5.  Outcomes of anatomical vs. functional testing for coronary artery disease : Lessons from the major trials.

Authors:  Júlia Karády; Jana Taron; Andreas Anselm Kammerlander; Udo Hoffmann
Journal:  Herz       Date:  2020-08       Impact factor: 1.443

6.  An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group.

Authors:  Vijay Kunadian; Alaide Chieffo; Paolo G Camici; Colin Berry; Javier Escaned; Angela H E M Maas; Eva Prescott; Nicole Karam; Yolande Appelman; Chiara Fraccaro; Gill Louise Buchanan; Stephane Manzo-Silberman; Rasha Al-Lamee; Evelyn Regar; Alexandra Lansky; J Dawn Abbott; Lina Badimon; Dirk J Duncker; Roxana Mehran; Davide Capodanno; Andreas Baumbach
Journal:  Eur Heart J       Date:  2020-10-01       Impact factor: 29.983

7.  Prognosis of CT-derived Fractional Flow Reserve in the Prediction of Clinical Outcomes.

Authors:  Charis G McNabney; Stephanie L Sellers; Ryan J A Wilson; Shmuel Hart; Samuel A Rosenblatt; Darra T Murphy; Philipp Blanke; Amir A Ahmadi; Jaydeep Halankar; Adrian Attinger-Toller; Marcelo Godoy Zamorano; Janice Wong Li Yu; Bjarne L Nørgaard; Jonathon A Leipsic; Jonathan R Weir-McCall
Journal:  Radiol Cardiothorac Imaging       Date:  2019-06-27

8.  The association between intravascular ultrasound-derived echo-attenuation and quantitative flow ratio in intermediate coronary lesions.

Authors:  Liang Geng; Yuan Yuan; Peizhao Du; Liming Gao; Yunkai Wang; Jiming Li; Wei Guo; Ying Huang; Qi Zhang
Journal:  Cardiovasc Diagn Ther       Date:  2021-12

9.  Analysis of FFR Measurement Clinical Impact and Cost-Effectiveness Compared to Angiography In Multi-Arterial Patients Undergoing PCI.

Authors:  Fernando Mendes Sant'Anna; Lucas Bonacossa Sant'Anna
Journal:  Arq Bras Cardiol       Date:  2019-01       Impact factor: 2.000

10.  QFR Predicts the Incidence of Long-Term Adverse Events in Patients with Suspected CAD: Feasibility and Reproducibility of the Method.

Authors:  Andrea Buono; Annika Mühlenhaus; Tabitha Schäfer; Ann-Kristin Trieb; Julian Schmeißer; Franziska Koppe; Thomas Münzel; Remzi Anadol; Tommaso Gori
Journal:  J Clin Med       Date:  2020-01-14       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.